0RI

Orladeyo

Find entries where: 0RI

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	Orladeyo
Identifiers	2-[3-(aminomethyl)phenyl]-~{N}-[5-[(~{R})-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluoranyl-phenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
Formula	C₃₀ H₂₆ F₄ N₆ O
Molecular Weight	562.561
Type	NON-POLYMER
Isomeric SMILES	c1cc(cc(c1)n2c(cc(n2)C(F)(F)F)C(=O)Nc3cc(ccc3F)[C@@H](c4cccc(c4)C#N)NCC5CC5)CN
InChI	InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1
InChIKey	UXNXMBYCBRBRFD-MUUNZHRXSA-N

Chemical Details
Formal Charge	0
Atom Count	67
Chiral Atom Count	1
Bond Count	71
Aromatic Bond Count	23

Drug Info: DrugBank

DrugBank ID	DB15982
Name	Berotralstat
Groups	approved
Description	Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE).[L26661] It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.[A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules.[A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older.[L26661] Berotralstat was approved by the European Commission on April 30, 2021 [L41965] and by Health Canada on June 06, 2022.[L41960]
Synonyms	BCX7353 Berotralstat hydrochloride (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Berotralstat (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3- cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride
Brand Names	Orladeyo
Indication	Berotralstat is indicated for prophylaxis of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. It is not used for the treatment of acute HAE attacks.[L26661,L41965,L41990]
Categories	BCRP/ABCG2 Substrates Blood and Blood Forming Organs Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors (moderate) Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (moderate) Cytochrome P-450 Enzyme Inhibitors Drugs Used in Hereditary Angioedema Enzyme Inhibitors Kallikrein Inhibitors Kallikreins, antagonists & inhibitors Moderate Risk QTc-Prolonging Agents P-glycoprotein inhibitors P-glycoprotein substrates Plasma Kallikrein Inhibitor Protease Inhibitors QTc Prolonging Agents Serine Protease Inhibitors
ATC-Code	B06AC06
CAS number	1809010-50-1

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Plasma kallikrein	MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMR...	unknown	inhibitor
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	inhibitor
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate,inhibitor
ATP-binding cassette sub-family G member 2	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682